Sabatolimab, a novel anti-TIM3 monoclonal antibody, exerts its antileukemic activity by a direct targeting of TIM-3 on the blast surface, promotes antibody-dependent phagocytosis, and promotes the block of TIM-3–GALAECTIN-9 interaction, preventing leukemia stem cell renewal [140]. The gene discussed is HAVCR2; the disease is leukemia.